Search results
Results From The WOW.Com Content Network
Shares of the California-based company fell 16% in extended trading. The decision comes after two failed attempts to secure regulatory approval for the expanded use of pimavanserin in the ...
Acadia's drug, trofinetide, to treat Rett syndrome, a genetic brain disorder, was launched in the U.S. last year under the brand name Daybue. "Acadia has misrepresented Daybue's safety profile ...
ACADIA Pharmaceuticals was on fire yesterday, up 24% after presenting data for its antipsychotic pimavanserin at the American Academy of Neurology annual meeting. The data looked good.
Acadia had partnered with Biovail in the late-stage clinical testing of the drug, which showed trial failures as of 2009. [ 5 ] [ 6 ] [ 7 ] Acadia is running multiple Phase 2 and Phase 3 trials with pimavanserin in several central nervous system conditions: dementia -related psychosis, [ 8 ] major depressive disorder , [ 9 ] schizophrenia ...
Has Wall Street gone a bit overboard punishing ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)? The drug maker’s share price continues to fall Wednesday on the heels of a disappointing 4Q earnings ...
The stock of ACADIA Pharmaceuticals (NAS:ACAD, 30-year Financials) appears to be possible value trap, according to GuruFocus Value calculation.
For premium support please call: 800-290-4726 more ways to reach us
In this article you are going to find out whether hedge funds think ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is a good investment right now. We like to check what the smart money thinks first ...